[미국특허]
Fused quartz tubing for pharmaceutical packaging
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C03C-003/06
A61J-001/00
B65D-001/00
C03C-004/00
C03B-001/00
출원번호
US-0477396
(2012-05-22)
등록번호
US-9399000
(2016-07-26)
발명자
/ 주소
Ahn, Kipyung
Xu, Guangjun
Panchula, Martin
Conzone, Samuel
Rong, Tianjun
Zuyev, Konstantin S.
Zhou, Yen
출원인 / 주소
Momentive Performance Materials, Inc.
대리인 / 주소
McDonald Hopkins LLC
인용정보
피인용 횟수 :
0인용 특허 :
32
초록▼
A high silica glass composition comprising about 92 to about 99.9999 wt. % SiO2 and from about 0.0001 to about 8 wt. % of at least one dopant selected from Al2O3, CeO2, TiO2, La2O3, Y2O3, Nd2O3, other rare earth oxides, and mixtures of two or more thereof. The glass composition has a working point t
A high silica glass composition comprising about 92 to about 99.9999 wt. % SiO2 and from about 0.0001 to about 8 wt. % of at least one dopant selected from Al2O3, CeO2, TiO2, La2O3, Y2O3, Nd2O3, other rare earth oxides, and mixtures of two or more thereof. The glass composition has a working point temperature ranging from 600 to 2,000° C. These compositions exhibit stability similar to pure fused quartz, but have a moderate working temperature to enable cost effective fabrication of pharmaceutical packages. The glass is particularly useful as a packaging material for pharmaceutical applications, such as, for example pre-filled syringes, ampoules and vials.
대표청구항▼
1. A pharmaceutical packaging container comprising a silica glass composition comprising about 92 to about 99.9 wt. % SiO2 and about 0.1 to about 8 wt. % selected from Al2O3, GeO2, Ga2O3, CeO2, ZrO2, TiO2, Y2O3, a rare earth oxide, or mixtures of two or more thereof, wherein the composition does not
1. A pharmaceutical packaging container comprising a silica glass composition comprising about 92 to about 99.9 wt. % SiO2 and about 0.1 to about 8 wt. % selected from Al2O3, GeO2, Ga2O3, CeO2, ZrO2, TiO2, Y2O3, a rare earth oxide, or mixtures of two or more thereof, wherein the composition does not contain an appreciable amount of alkali metals, alkaline earth metals, or borate ions. 2. The pharmaceutical packaging container of claim 1, where the silica glass composition comprises about 96 to about 99.9 wt % SiO2. 3. The pharmaceutical packaging container of claim 1, where the container is formed by thermal conversion processing of a glass article formed from the silica glass composition. 4. The pharmaceutical packaging container of claim 1 in the form of one of a vial, cartridge, syringe barrel, or ampoule. 5. The pharmaceutical packaging container of claim 1, wherein said container is designed for the liquid or dry (lyophilized) storage of drugs. 6. The pharmaceutical packaging container of claim 1, wherein the inner surface of the packaging container is substantially free of a coating. 7. The pharmaceutical packaging container of claim 1, wherein the container has a total extractable metal concentration of about 8 mg/L or less when subjected to HCl digestion, the total extractable metal concentration being represented by the total concentration of Al, B, Na, Ca, K, Li, Ba, and Mg extracted upon HCl digestion. 8. The pharmaceutical packaging container of claim 1, wherein the container exhibits the following leaching characteristics when subjected to HCl digestion: Na (<7.0 mg/L), Ca (<1.0 mg/L), B (<2.5 mg/L), Al (<1.25 mg/L), Ba (<0.003 mg/L), K (<0.03 mg/L), or Mg (<0.01 mg/L). 9. The pharmaceutical packaging container of claim 1, wherein the container exhibits the following leaching characteristics when subjected to HCl digestion: Na (<0.1 mg/L), Ca (<0.05 mg/L), B (<0.01 mg/L), Al (<0.05 mg/L), K(<0.01 mg/L), or Mg (<0.01 mg/L). 10. The pharmaceutical packaging container of claim 1, wherein the total concentration of metal impurities is about 0.5 wt. % or less. 11. The pharmaceutical packaging container of claim 1, wherein the total concentration of metal impurities is about 0.015 wt. % or less. 12. The pharmaceutical packaging container of claim 1, wherein the container produces 1000 particles/cm2 or less when in contact with a pharmaceutical aqueous solution at pH from about 3 to 10 for 60 days. 13. The pharmaceutical packaging container of claim 1, wherein the container produces 500 particles/cm2 or less when in contact with a pharmaceutical aqueous solution at pH from about 3 to 10 for 60 days. 14. The pharmaceutical packaging container of claim 1, wherein the container produces 100 particles/cm2 or less when in contact with a pharmaceutical aqueous solution at pH from about 3 to 10 for 60 days. 15. The pharmaceutical packaging container of claim 1, wherein the container produces 50 particles/cm2 or less when in contact with a pharmaceutical aqueous solution at pH from about 3 to 10 for 60 days. 16. The pharmaceutical packaging container of claim 1, wherein the container produces 10 particles/cm2 or less when in contact with a pharmaceutical aqueous solution at pH from about 3 to 10 for 60 days. 17. The pharmaceutical packaging container of claim 1, wherein the container has a OH concentration of 0.5% or less, a Cl concentration of 0.5% or less, or a OH concentration and Cl concentration of 0.5% or less. 18. The pharmaceutical packaging container of claim 1, wherein the container has a OH concentration of 150 ppm or less, a Cl concentration 150 ppm or less, or a OH concentration and Cl concentration of 150 ppm or less. 19. The pharmaceutical packaging container of claim 1, wherein the container has a OH concentration of 50 ppm or less, a Cl concentration of 50 ppm or less, or a OH concentration and Cl concentration of 50 ppm or less. 20. The pharmaceutical packaging container of claim 1, wherein the container has a OH concentration of 10 ppm or less, a Cl concentration of 10 ppm or less, or a OH concentration and Cl concentration of 10 ppm or less. 21. The pharmaceutical packaging container of claim 1, wherein the concentration of cations or metal ions leached from the container is lower than the concentration of cations or metals leached from a borosilicate glass and/or soda lime glass when the respective glasses are in contact with an aqueous solution. 22. The pharmaceutical packaging container of claim 1, wherein the container is formed by a continuous draw process comprising drawing a glass composition into a rod or tube, and converting the rod or tube into the container. 23. The pharmaceutical packaging container of claim 1, wherein the container is formed from a glass composition comprising a fine metal oxide dispersing agent. 24. The pharmaceutical packaging container of claim 21, wherein the aqueous solution is a liquid pharmaceutical drug formulation. 25. A pharmaceutical packaging container comprising a silica glass composition comprising at least 99.9% wt. % SiO2 and a dopant selected from Al2O3, GeO2, Ga2O3, CeO2, ZrO2, TiO2, Y2O3, a rare earth oxide, or mixtures of two or more thereof in an amount of about 0.1 to about 0.0001 wt. %. 26. The pharmaceutical packaging container of claim 25 comprising greater than about 99.95 wt. % SiO2.
Meulemans Charles C. E. (Eindhoven NLX) van der Steen Gerardus H. A. M. (Eindhoven NLX) van Werkhoven Jan (Eindhoven NLX), High pressure discharge lamp with vessel having a UV radiation absorbing portion of quartz glass.
Parham Thomas G. (Gates Mills OH) Bateman ; Jr. Robert L. (Kitty Hawk NC) Allen Gary R. (Chesterland) Mathews Paul G. (Chesterland OH), High temperature lamps having UV absorbing quartz envelope.
TenEyck John D. (Lewiston NY) Clere Thomas M. (Williamsville NY) Olson James (Youngstown NY) Waisala Steven (Aurora OH), High temperature stable continuous filament glass ceramic fibers.
van der Steen Gerardus H. A. M. (Eindhoven NLX) Van Hove Eddy F. C. (Eindhoven NLX), Lamp having a lamp vessel made of quartz glass, quartz glass and method of preparing quartz glass.
Walther Marten,DEX ; Spallek Michael,DEX ; Danielzik Burkhardt,DEX ; Heming Martin,DEX ; Segner Johannes,DEX, Method of making a hollow, interiorly coated glass body and a glass tube as a semi-finished product for forming the glass body.
Sato, Tatsuhiro; Yoshida, Nobumasa; Fujinoki, Akira; Inaki, Kyoichi; Shirai, Tomoyuki, Quartz glass body having improved resistance against plasma corrosion, and method for production thereof.
Sato, Tatsuhiro; Yoshida, Nobumasa; Fujinoki, Akira; Inaki, Kyoichi; Shirai, Tomoyuki, Quartz glass body having improved resistance against plasma corrosion, and method for production thereof.
Scott Curtis E. (Mentor OH) Secen Cynthia A. (Mentor OH) Parham Thomas G. (Gates Mills OH) Allen Gary R. (Chesterland OH) Bateman ; Jr. Robert L. (Southern Shores NC) Mathews Paul G. (Chesterland OH), UV absorbing fused quartz and its use for lamp envelopes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.